Evidence map›Paper›PMID 32363603›Full record

ArticleStatistics in medicine2020

Point and interval estimation in two-stage adaptive designs with time to event data and biomarker-driven subpopulation selection.

Peter K Kimani, Susan Todd, Lindsay A Renfro, Ekkehard Glimm, Josephine N Khan, John A Kairalla, Nigel Stallard

Open access · hybridAbstract read
In one paragraph

Article in Statistics in medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 3 countries.

Peter K KimaniWarwick Medical School, University of Warwick, Coventry, UK.ORCID 0000-0001-8200-3173
Susan ToddDepartment of Mathematics and Statistics, University of Reading, Reading, UK.
Lindsay A RenfroDivision of Biostatistics, University of Southern California, Los Angeles, CA, USA.
Ekkehard GlimmNovartis Campus, Novartis Pharma AG, Basel, Switzerland.
Josephine N KhanMRC Biostatistics Unit, University of Cambridge, Cambridge, UK.
John A KairallaDepartment of Biostatistics, University of Florida, Gainesville, Florida, USA.
Nigel StallardWarwick Medical School, University of Warwick, Coventry, UK.
University of Warwick · GBNovartis (Switzerland) · CHUniversity of Cambridge · GBUniversity of Florida · USUniversity of Reading · GBUniversity of Southern California · US

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
Medical Research Council MR/N028309/1NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899
6 · The paper itself

Abstract

In personalized medicine, it is often desired to determine if all patients or only a subset of them benefit from a treatment. We consider estimation in two-stage adaptive designs that in stage 1 recruit patients from the full population. In stage 2, patient recruitment is restricted to the part of the population, which, based on stage 1 data, benefits from the experimental treatment. Existing estimators, which adjust for using stage 1 data for selecting the part of the population from which stage 2 patients are recruited, as well as for the confirmatory analysis after stage 2, do not consider time to event patient outcomes. In this work, for time to event data, we have derived a new asymptotically unbiased estimator for the log hazard ratio and a new interval estimator with good coverage probabilities and probabilities that the upper bounds are below the true values. The estimators are appropriate for several selection rules that are based on a single or multiple biomarkers, which can be categorical or continuous.

Indexed as

Precision MedicineResearch DesignBiomarkersHumansPatient SelectionProbabilityBiomarkersadaptive threshold designenrichment designsstratified medicinesubgroup analysissurvival data

Identifiers

PMID32363603
PMCPMC7785132
OpenAlexW3023339592

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.